

THROMBOSIS AND COAGULOPATHY IN COVID-19

Juan Esteban Gómez-Mesa MD, FSIAC ,
Stephania Galindo-Coral MD , Maria Claudia Montes MD ,
Andrés J. Muñoz Martin MD, PhD

PII: S0146-2806(20)30218-8
DOI: https://doi.org/10.1016/j.cpcardiol.2020.100742
Reference: YMCD 100742

To appear in: *Current Problems in Cardiology*

Please cite this article as: Juan Esteban Gómez-Mesa MD, FSIAC , Stephania Galindo-Coral MD , Maria Claudia Montes MD , Andrés J. Muñoz Martin MD, PhD , THROMBOSIS AND COAGULOPATHY IN COVID-19, *Current Problems in Cardiology* (2020), doi: https://doi.org/10.1016/j.cpcardiol.2020.100742

TITLE:

THROMBOSIS AND COAGULOPATHY IN COVID-19

AUTHORS:

Juan Esteban Gómez-Mesa, MD, FSIAC[1,2,3,*], Stephania Galindo-Coral, MD[1], Maria Claudia Montes, MD[1], Andrés J. Muñoz Martin, MD, PhD[4,5]

AFFILIATIONS:

[1]Cardiology department, Fundación Valle del Lili. Cali, Colombia.

[2]Faculty of health science, Universidad Icesi. Cali, Colombia.

[3]Interamerican Society of Cardiology.

[4]Medical Oncology Service, Hospital General Universitario Gregorio Marañón. Madrid, Spain.

[5]Universidad Complutense de Madrid. Madrid, Spain.

[*]**Corresponding author**: Dr Juan Esteban Gomez-Mesa

Cardiology Service

Cra. 98 N. 18-49

Fundación Valle del Lili

Cali-Colombia.

E-mail: juan.gomez.me@fvl.org.co

ABSTRACT:

Since December 2019, an outbreak of coronavirus disease 2019 (*COVID-19*) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on 11 March 2020, the World Health Organization declared the new Coronavirus disease 2019 (*COVID-19*) as a pandemic. The presence of comorbidities (*e.g.: cardiovascular disease, obesity*), SIC score> 4, elevation of D-dimer *(> 6 times the normal value*), C-reactive protein, troponins and other DIC markers; is associated to a worse prognosis in hospitalized patients with severe COVD-19, reaching a hospital mortality of 42%. Initial anticoagulant treatment with LMWH has been shown to reduce mortality by 48% at 7 days and 37% at 28 days and achieve a significant improvement in the arterial oxygen pressure / inspired fraction of O2 (*PaO2 / FiO2*) by mitigating the formation of microthrombi and associated pulmonary coagulopathy.

KEY WORDS:

Coronavirus 2019, thromboprophylaxis, thromboembolism, coagulopathy, thrombosis, anticoagulant, SARS-CoV-2

ABBREVIATIONS

ACS, Acute Coronary Syndrome

AMI, Acute Myocardial Infarction

ARDS, Acute Respiratory Distress Syndrome

CVD, Cerebrovascular Event

DIC, Disseminated Intravascular Coagulation

DOACs, Direct Oral Anticoagulants

DVT, Deep Vein Thrombosis

HnF, Unfractionated Heparin

ICU, Intensive Care Unit

INR, International Normalized Ratio

IL, Interleukin

ISTH, International Society of Thrombosis and Haemostasis

LMWH, Low Molecular Weight Heparin

MV, Mechanical ventilation

PTE, Pulmonary Thromboembolism

PTT, Partial Thromboplastin Time

SIC, Sepsis Induced Coagulopathy

SOFA, Sequential Organ Failure Assessment

TP, Prothrombin Time

VTE: Venous Thromboembolism

EPIDEMIOLOGY

Since December 2019, an outbreak of coronavirus disease 2019 (*COVID-19*) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world. On February 11, 2020, the Coronavirus Study Group of the International Committee on Taxonomy of Viruses officially named the new coronavirus that causes COVID-19 as "severe acute respiratory syndrome coronavirus 2 (*SARS-CoV-2*)", and on 11 March 2020, the World Health Organization declared the new Coronavirus disease 2019 (*COVID-19*) as a pandemic (1, 2, 3, 4, 5, 6, 7, 8).

This pandemic had its epicenter in the Asian continent (*China*), which later moved to the European continent (*mainly Italy and Spain*), and currently to the American continent, initially in the United States and now in United States and Latin America (*mainly Mexico and Brazil*) (*Graph # 1, #2 and #3*).

CORONAVIRUS-19 INFECTION

The "severe acute respiratory syndrome coronavirus 2 (*SARS-CoV-2*)" is a single stranded RNA coronavirus that enters the human cell mainly through binding to angiotensin converting enzyme 2 (*ACE 2*), expressed in increased amounts in the alveolar cell of the lung, cardiac myocytes, vascular endothelium, and other cells. SARS-CoV-2 is transmitted mainly after the viral particles are inhaled and enters the respiratory tract. This virus can survive for up to 24-72 hours on surfaces that allow its transmission (1, 6).

This respiratory viral infection produces the COVID-19, which is generally asymptomatic or with mild symptoms including fever, cough, fatigue, dyspnea, diarrhea, headache and myalgia (*up to 81.4% of patients*). Severe cases are characterized by respiratory rate> 30 bpm, arterial oxygen saturation <93% at rest, PaO2 / FiO2 <300 mmHg and / or infiltrates in > 50% of lung fields in 24-48 hours (*up to 13.9% of patients*) and can progress to critically ill patients (*up to 4.7% of patients*), presenting rapid deterioration and development of acute respiratory distress syndrome (*ARDS*), septic shock, metabolic acidosis and coagulopathy, including disseminated intravascular coagulation (*DIC*) and cytokine storm (2, 4 , 7, 8, 9, 10, 11, 12, 13).

These clinical manifestations, as well as the imaging and paraclinical alterations, vary as the pandemic evolves worldwide, and they also depend on the severity of the infection. A registry of 1,099 laboratory-confirmed COVID-19 patients in 552 institutions in 30 provinces of China described some of these most frequent and relevant findings, observed in the first two months of this pandemic (***Table # 1***) (8).

The most consistent hemostatic alterations with COVID-19 are thrombocytopenia and elevation of D-dimer, which are associated with a higher requirement for mechanical ventilation (*MV*), admission to intensive care, and death. It has been described that older patients and those with comorbidities have a higher risk of in-hospital mortality, and in these two groups of patients there are also higher levels of D-dimer. Taking into account the clinical implications of the elevated D-dimer value or the marked elevations during

follow-up (*3 - 4 times*), hospital management can be considered in this setting in the absence of other severe symptoms since this indicates an increase in thrombin generation and a greater risk of complications (***Table # 2 and # 3***) (14 , 15, 16).

COAGULOPATHY

In hospitalized patients for suspected or confirmed COVID-19, a coagulation profile should be performed, including D-dimer, PT, PTT, platelet count, and fibrinogen. Alterations in these parameters can occur 7-11 days after the onset of symptoms or 4-10 days after hospitalization. Repeating these coagulopathy parameters (*D-dimer, prothrombin time, and platelet count*) are recommended in patients with severe COVID-19, at least every 2 - 3 days (6, 15).

The combination of thrombocytopenia, prolonged PT, and elevated D-dimer suggests DIC, however, its presentation is different from the presentation seen in sepsis, where thrombocytopenia is much more profound and the elevation of D-dimer does not reach the values observed in COVID-19 cases. Current evidence suggests COVID-19 associated coagulopathy is a combination of low-grade DIC and pulmonary thrombotic microangiopathy, which could have a significant impact on organ dysfunction in most patients with severe disease (14).

The presence of coagulopathy as part of the systemic inflammatory response syndrome is a common feature of severe COVID-19. Approximately 20% to 50% of hospitalized patients

with COVID-19 have hematologic changes in coagulation tests (*elevated D-dimer, prolonged PT, thrombocytopenia, and / or low fibrinogen levels*). This condition is characterized by more thrombotic than hemorrhagic events that are associated with coagulopathy (*specifically VTE*). On the other hand, endothelial dysfunction results in high levels of D-dimer, thrombin and fibrin degradation products, thrombocytopenia and prolonged clotting times, which leads to hypoxia and pulmonary congestion mediated by thrombosis and microvascular occlusion, in addition to thrombosis of central lines and catheters and vascular occlusive events (*cerebrovascular events, limb ischemia, etc.*) that generally occur in the intensive care units (6, 10, 15, 17, 18, 19).

Fibrin and thrombin deposition occurs mainly in the pulmonary microvasculature, being a factor that contributes to ARDS and coagulopathy in patients who die from COVID-19. Furthermore, the hypoxia that occurs in severe COVID-19 can aggravate thrombosis not only by increasing the viscosity of the blood, but also through the hypoxia-inducible transcription factor-dependent signaling pathway (10, 17, 20).

Similar to the endothelial dysfunction of SIC, in which there is excessive thrombin generation and impaired fibrinolysis, there is a type of endotheliopathy that appears to contribute to the pathophysiology of microcirculatory changes in SARS-CoV-2 infection. The receptor for viral adhesion is an angiotensin-converting enzyme-2 receptor on endothelial cells, and viral replication causes inflammatory cell infiltration, endothelial apoptosis, and microvascular prothrombotic events. Viral inclusions within endothelial

cells and mononuclear and polymorphonuclear cell infiltration have been observed, with evidence of endothelial apoptosis in postmortem analysis of SARS-Cov-2 infection. As a result of this, microcirculatory dysfunction contributes to the clinical sequelae of COVID-19 patients (6, 10). Other abnormalities that may be relevant in the context of coagulopathy are decreased fibrinogen, elevated LDH, and, in some patients, markedly elevated serum ferritin values (20).

Another important characteristic of COVID-19 infection is the procoagulant response in its acute phase, where acute phase reactants (*such as Factor VIII, Von Willebrand Factor, and fibrinogen*) are associated with an increased risk of thrombosis directly related to elevated levels of fibrinogen. In severe stages of the disease, there is an increase in inflammatory cytokines (*tumor necrosis factor and interleukins, including interleukin 1 and interleukin 6*). IL-6 induces expression of tissue factor in macrophages, which initiates the activation of coagulation and generation of thrombin. Tumor necrosis factor and IL-1 are the main mediators of the suppression of the endogenous coagulation cascade. In a group of severely compromised COVID-10 patients, a cytokine storm characterized by high concentrations of pro-inflammatory cytokines and chemokines may be found (12, 14).

The ISTH proposed a new category to identify an early stage of DIC associated with sepsis, which is called SIC. This score can be applied to COVID-19 patients, and those who meet these criteria benefit from anticoagulant management (***Table # 4***) (7, 10).

Up to 71.4% of patients who die from COVID-19 have DIC, while it occurs in only 0.6% in those who survive. The main alteration of this coagulopathy is the marked elevation of D-dimer without a drop in platelets or a prolongation of clotting times, which suggests a process of generation of thrombin and local rather than systemic fibrinolysis. D-dimer value> 2.0 ug / ml at admission or its increase during hospitalization (*up to 3-4 times*) have been associated with higher hospital mortality (18, 20, 21, 22).

The worsening of laboratory parameters related to coagulation indicates progression in the severity of COVID-19 infection and predicts the need for greater and more aggressive intensive care, while the improvement of these parameters, together with the improvement or clinical stability suggest an adequate evolution (18)

VENOUS THROMBOEMBOLISM

COVID-19 infection can predispose to VTE or arterial due to the presence of increased inflammatory response, hypoxia, immobilization, and DIC (7, 10, 21).

The risk of developing VTE in critically ill patients is higher in the presence of COVID-19. In addition to hemostatic alterations; immobility, systemic inflammatory status, mechanical ventilation and central catheters increase the risk of thromboembolic events, while nutritional and hepatic alterations vary the production of coagulation factors (1). There are several studies that support the increased incidence of VTE in COVID-19 patients and

their risk factors (13, 21, 23, 24, 25) (***Table #5***). Other study found that the proportion of patients with VTE was higher in the ICU patients (*47%; 95% CI, 36-58*) than in the general ward patients (*3.3%; 95% CI, 1.3-8.1*) (***Table # 6***); the risk factors for VTE that were identified include ICU hospitalization, higher leukocyte count, higher neutrophil / lymphocyte ratio, and higher D-dimer value (25).

In patients with sudden deterioration in oxygen saturation, respiratory distress, low blood pressure, or right ventricular dysfunction, the possibility of PE should be considered. Diagnosis can be difficult as COVID-19 patients may have an elevated D-dimer value even in the absence of VTE. Imaging studies cannot be done routinely due to the risk of transmission of the infection, the limitations to transfer and the clinical instability that the patient could present at any given time. In these cases, and taking into account the value of D-dimer, the use of anticoagulants at therapeutic, intermediate doses or as prophylaxis could be considered. The use of tests at the patient side, such as compression ultrasonography for the diagnosis of DVT and echocardiography to evaluate RV strain associated with PE, can be difficult in unstable, prone, or critically ill patients; also, without having sufficient specificity and sensitivity to diagnose VTE, in certain clinical scenarios they can increase the index of clinical suspicion, and its use may be considered (1, 25).

THROMBOPROPHYLAXIS (*Table # 7*)

Hospitalized patients with COVID-19 present similar intrinsic and extrinsic risk factors for VTE to the rest of the hospitalized population, such as advanced age, obesity, immobilization, neurological events, cancer, ICU management, previous thromboembolic events or thrombophilia, however, prophylactic management in this population is currently a challenge (25).

Pharmacological thromboprophylaxis should then be considered in all hospitalized COVID-19 patients who are immobilized or severely ill, unless there are contraindications (*such as active bleeding or severe thrombocytopenia*). Different scales can be used to assess this hospital risk (*Padua, Caprini, IMPROVE*). The dose should be adjusted according to renal function. Although drug selection should be guided by available institutional protocols, the World Health Organization recommends the use of unfractionated or low molecular weight heparins and, if contraindicated, mechanical thromboprophylaxis should be considered. Pharmacological thromboprophylaxis is recommended once a day, since it reduces the risk of missing additional doses and is also associated with less exposure of health personnel for its administration. If LMWH is not available, unfractionated heparin can be considered, keeping in mind that this requires more frequent injections and, therefore, greater exposure of health personnel. Fondaparinux can also be considered, but there is no evidence that this molecule has the same anti-inflammatory properties as heparins. Patients with more severe infections may require higher doses of thromboprophylaxis due to their hypercoagulable state. The use of direct anticoagulants

in thromboprophylaxis is not recommended in this context due to the possible drug interactions that may occur with the different drugs and therapies available and under investigation for the treatment of COVID-19 (4, 14, 15, 25).

Some of the non-anticoagulant properties of LMWH include the potential for binding to inflammatory cytokines, inhibition of neutrophil chemotaxis and leukocyte migration, neutralization of positively charged complement factor C5a, and sequestration of acute phase proteins (12, 26).

Regarding the above, it is suggested that LMWH administered in the early stages of SARS-CoV2 infection can exert a positive effect not only in terms of preventing thrombosis but also reducing systemic and pulmonary inflammation and limiting viral invasion (7, 13).Other non-anticoagulant actions of heparin include its antiviral role (*experimental models*), decreased collagen deposits and antiarrhythmic properties *(animal models*), as well as modulation of endothelial dysfunction, improvement of microvascular dysfunction, and mitigation of pulmonary coagulopathy (26 , 27).

In patients who remain completely immobilized, there may be an additional benefit with intermittent pneumatic compression in addition to drug thromboprophylaxis. This therapy should also be considered if there is severe thrombocytopenia (*platelets <25,000 to 50,000 x 10^9 / L*) (2, 25, 28, 29).

The use of extended ambulatory thromboprophylaxis (*from 14 to 45 days*) should be considered in patients at high risk of venous thromboembolism, independent of COVID-19 infection, and that includes reduced mobility, previous thromboembolic events, comorbidities (*e.g.: active cancer*) and Elevated D-dimer *(> 2 times normal value*). Thromboprophylaxis for patients who are quarantined for mild COVID-19, but with significant comorbidities, or patients without COVID-19 but who are functionally severely limited by quarantine is not recommended. These patients should be advised to remain active at home (1, 2, 25).

ANTICOAGULATION (*Table # 7*)

The presence of comorbidities (*e.g.: cardiovascular disease, obesity*), SIC score> 4, elevation of D-dimer *(> 6 times the normal value*), C-reactive protein, troponins and other DIC markers; (***Table # 4***) is associated to a worse prognosis in hospitalized patients with severe COVD-19, reaching a hospital mortality of 42% (25).

In this population, initial anticoagulant treatment with LMWH has been shown to reduce mortality by 48% at 7 days and 37% at 28 days and achieve a significant improvement in the arterial oxygen pressure / inspired fraction of O2 (*PaO2 / FiO2*) by mitigating the formation of microthrombi and associated pulmonary coagulopathy, also decreasing complementary inflammation (26, 30, 31).

Anticoagulation should be considered if there is evidence of VTE or if the patient is anticoagulated, unless they have thrombocytopenia *(<50,000 x mm x or active bleeding*). The selected drug depends on kidney and liver function, platelet count, and gastrointestinal function. Parenteral anticoagulation is recommended in critically ill patients, as it can be temporarily suspended and has no interactions with drugs considered for the treatment of COVID-19. Given the exposure of health personnel with the use of unfractionated heparin by taking paraclinics and dose adjustment, the use of low molecular weight heparins is preferred in these patients. The benefits of DOACs include no need for routine monitoring and easy outpatient management, however, potential risks may include their use in the presence of clinical deterioration and the lack of availability of a reversal agent in all institutions. In patients who are going to be discharged, the use of DOACs and LMWH should be preferred, avoiding frequent tests for INRs. The potential for drug interactions with potential treatments for COVID-19 should always be evaluated (1, 5, 7, 14, 18) (***Table #8***).

A 30-50% decrease in platelet count from the start of heparin treatment (4 to 14 days) should suggest heparin-induced thrombocytopenia. The foregoing makes it necessary to suspend this anticoagulant treatment, and may explain some cases of limb ischemia that have been observed in cases of COVID-19 (15).

CONCLUSIONS

There are different ways in which the COVID-19 pandemic can affect the prevention and treatment of thrombotic or thromboembolic diseases. First, the direct effect of COVID-19 or the indirect effect related to the cytokine storm that precipitates the onset of the systemic inflammatory response syndrome and predisposes to the development of thrombotic events; second, the interventions available to treat COVID-19 (*e.g., lopinavir / ritonavir, remdesivir, bevacizumab, tocilizumab, sarilumab, fingolimod, chloroquine / hydroxychloroquine, interferon, azithromycin*) may have drug interactions with antiplatelets and / or anticoagulants; and third, the pandemic, due to the redistribution of resources and social distancing recommendations, can adversely affect the care of patients without COVID-19 but who present thrombotic events and the fear of acquiring COVID-19 or presenting complications leads to not receiving or suspending the anticoagulant treatment (1).

The protocols for thromboprophylaxis, anticoagulation, and additional considerations for the management of coagulopathy and bleeding should be implemented in each institution following the most current national and international recommendations.

FUNDING:

None

CONFLICT OF INTEREST:

The authors report no conflict of interest.

REFERENCES

1. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75 (23):2950-2973. doi:10.1016/j.jacc.2020.04.031
2. Boccia M, Aronne L, Celia B, et al. COVID-19 and coagulative axis: review of emerging aspects in a novel disease. Monaldi Archives for Chest Disease. 2020; 90 (1300): 271 – 276. doi:10.4081/monaldi.2020.1300
3. Song JC, Wang G, Zhang W, et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res. 2020;7 (1):19. doi.org/10.1186/s40779-020-00247-7
4. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance V 1.2. 13 march 2020; 1 – 21
5. Günertem E, Akay T, Aliyev A, et al. Treatment and prophylaxis strategies for deep vein thrombosis during COVID-19 outbreak. Turk J Vasc Surg. 2020;29 (3):203-207. doi.org/ 10.9739/tjvs.2020.734
6. Connors J, Levy J. COVID-19 and its implications for thrombosis and anticoagulation. Blood. Blood. 2020;135 (23): 2033–2040. doi.org/10.1182/blood.2020006000
7. Vivas D, Roldán V, Esteve-Pastor MA, et al. Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del Grupo de Trabajo

de Trombosis Cardiovascular de la Sociedad Española de Cardiología. Rev Esp Cardiol. 2020;73 (9):749-757. doi:10.1016/j.recesp.2020.04.006

8. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382 (18):1708-1720. doi:10.1056/NEJMoa2002032
9. Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020;323 (16):1612-1614. doi:10.1001/jama.2020.4326
10. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 in patients with coagulopathy. J Thromb Haemost. 2020; doi: 10.1111/jth.14817
11. China CDC. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. China CDC Weekly 2020; 2: 113 – 22
12. Marietta M, Ageno W, Artoni A, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 2020;18 (3):167-169. doi:10.2450/2020.0083-20
13. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. doi:10.1016/j.thromres.2020.04.024
14. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7 (6):e438-e440. doi:10.1016/S2352-3026 (20)30145-9

15. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18 (5):1023-1026. doi:10.1111/jth.14810

16. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395 (10229):1054-1062. doi:10.1016/S0140-6736 (20)30566-3

17. Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. J Thromb Haemost. 2020;18 (7):1752-1755. doi:10.1111/jth.14828

18. Lee AY, Connors JM, Kreuziger LB, et al. COVID-19 and Coagulopathy: Frequently Asked Questions. Hematology. 2020. Version 1.0

19. Lee SG, Fralick M, Sholzberg M. Coagulopathy associated with COVID-19. CMAJ. 2020;192 (21):E583. doi:10.1503/cmaj.200685

20. Covid Treatment Group. Thromboprophylaxis and anticoagulation in COVID-19 infection. Imperial College Healthcare – NHS. V 0.1 08.04.2020

21. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147. doi:10.1016/j.thromres.2020.04.013

22. Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18 (6):1324-1329. doi:10.1111/jth.14859

23. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18 (6):1421-1424. doi:10.1111/jth.14830

24. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18 (8):1995-2002. doi:10.1111/jth.14888

25. Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18 (8):1859-1865. doi:10.1111/jth.14929

26. Thachil J. The versatile heparin in COVID-19. J Thromb Haemost. 2020;18 (5):1020-1022. doi:10.1111/jth.14821

27. Menezes-Rodrigues FS, Padrão Tavares JG, Pires de Oliveira M, et al. Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients. J Thromb Haemost. 2020;18 (8):2073-2075. doi:10.1111/jth.14902

28. NICE guidelines Venous thromboembolism: reducing the risk for patients in hospital. http://www.nice.org.uk/guidance/cg92

29. Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2 (22):3198-3225. doi:10.1182/bloodadvances.2018022954

30. Li J, Li Y, Yang B, Wang H, et al. Low-molecular-weight heparin treatment for acute lung injury / acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2018; 11: 414 – 422

31. Mousavi S, Moradi M, Khorshidahmad T, Motamedi M. Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review. Adv Pharmacol Sci. 2015;2015:507151. doi:10.1155/2015/507151

BIBLIOGRAPHIC NOTE

- *Juan Esteban Gómez-Mesa:* MD, graduated as a Physician, later specialized in Internal Medicine and Cardiology. Currently, head of the Cardiology department from Fundación Valle del Lili Cali, Colombia; Coordinator of the Council for Heart Failure and Pulmonary Hypertension (CIFACAH) of the Inter-American Society of Cardiology (SIAC), Undergraduate / graduate teacher. Universidad Icesi. Cali, Colombia
- *Stephania Galindo-Coral:* MD, graduated from Universidad Icesi as a physician, part of the cardiology department and clinical research center from Fundación Valle del Lili, Cali, Colombia. Coordinator of the investigation lines for the cardiology department from this institution.
- *Maria Claudia Montes:* MD, graduated from Universidad Icesi as a physician, part of the cardiology department from Fundación Valle del Lili, Cali, Colombia. Currently,

  studying the master's degree in epidemiology. Coordinator of the investigation lines for the cardiology department from this institution.
- *Andrés J. Muñoz Martin* : PhD in Medicine from the Complutense University of Madrid. He works in the Digestive Cancer Unit of the Oncology Service of the Gregorio Marañón Hospital in Madrid. Vice President of the Ethics and Clinical Research Committee of the Hospital. Coordinator of the working group Cancer and Thrombosis of the Spanish Society of Medical Oncology (SEOM).

Tables and figures

Table 1. Most frequent clinical, imaging and paraclinical findings

	All (1.099)	Non Severe (926)	Severe (173)
Most frequent symptoms			
Cough	*745 (67.8%)*	*623 (67.3%)*	*122 (70.5%)*
Fever on admission (> 37.5 ° C)	*473/1081 (43.8%)*	*391/910 (43%)*	*82/171 (48%)*
Fatigue or tiredness	*419 (38.1%)*	*350 (37.8%)*	*69 (39.9%)*
Sputum production	*370 (33.7%)*	*309 (33.4%)*	*61 (35.3%)*
Shortness of breath	*205 (18.7%)*	*140 (15.1%)*	*65 (37.6%)*
Myalgia or arthralgia	*164 (14.9%)*	*134 (14.5%)*	*30 (17.3%)*
Odynophagia	*153 (13.9%)*	*130 (14.0%)*	*23 (13.3%)*
Headache	*150 (13.6%)*	*124 (13.4%)*	*26 (15.0%)*
Chill	*126 (11.5%)*	*100 (10.8%)*	*26 (15.0%)*
Imaging findings			
Chest X-ray changes	*162/274 (59.1%)*	*116/214 (54.2%)*	*46/60 (76.7%)*
Chest CT alterations	*840/975 (86.2%)*	*682/808 (84.4%)*	*158/167 (94.6%)*
Laboratory findings			
White blood cell count <4,000 mm^3	*330/978 (33.7%)*	*228/811 (28.1%)*	*102/167 (61.1%)*
Lymphocyte count <1,500 mm^3	*731/879 (83.2%)*	*584/726 (80.4%)*	*147/153 (96.1%)*
Platelet count <150,000 mm^3	*315/869 (36.2%)*	*225/713 (31.6%)*	*90/156 (57.7%)*
C-reactive protein ≥ 10 mg / L	*481/793 (60.7%)*	*371/658 (56.4%)*	*110/135 (81.5%)*

D-dimer ≥ 0.5 mg / L	*260/560 (46.4%)*	*195/451 (43.2%)*	*65/109 (59.6%)*

Table # 2. Conditions associated with hospital mortality

	Total (n=191)	**Death (n=54)**	**Alive (n=137)**	**p value**	**OR (95% CI)**	
					Univariable	**Multivariable**
Demographic conditions						
Age,years. Median (IQR)	*56 (46 - 67)*	*69 (63 – 76)*	*52 (45 – 58)*	*<0.0001*	*1.14 (1.09 – 1.18) p<0.0001*	*1.10 (1.03 – 1.17) p=0.0043*
Arterial hypertension. n (%)	*58 (30%)*	*26 (48%)*	*32 (23%)*	*0.0008*	*3.05 (1.57 – 5.92) p=0.001*	
Diabetes mellitus. n (%)	*36 (19%)*	*17 (31%)*	*19 (14%)*	*0.0051*	*2.85 (1.35 – 6.05) p=0.0062*	
Coronary heart disease. n (%)	*15 (8%)*	*13 (24%)*	*2 (1%)*	*<0.0001*	*21.40 (4.64 – 98.76) p<0.0001*	*2.14 (0.26 – 17.79) p=0.48*
COPD. n (%)	*6 (3%)*	*4 (7%)*	*2 (1%)*	*0.047*		
Respiratory rate> 24 bpm. n (%)	*56 (29%)*	*34 (63%)*	*22 (16%)*	*<0.0001*	*8.89 (4.34 – 18.19) p<0·0001*	

SOFA score. Median (IQR)	*2 (1 - 4)*	*4.5 (4 – 6)*	*1 (1 – 2)*	*<0.0001*	*6.14 (3.48– 10.85) p<0·0001*	
Laboratory findings						
Leukocytes,> 10,000 mm^3. n (%)	*40 (21%)*	*25 (46%)*	*15 (11%)*	*<0·0001*	*6.60 (3.02 – 14.41) p<0·0001*	
Lymphocytes, <800 mm^3. n (%)	*77 (40%)*	*41 (76%)*	*36 (26%)*	*<0.0001*	*0.02 (0.01 – 0.08) p<0·0001*	*0.19 (0.02 – 1.62) p=0·13*
Anemia. n (%)	*29 (15%)*	*14 (26%)*	*15 (11%)*	*0.0094*		
Platelets, <100,000mm^3. n (%)	*13 (7%)*	*11 (20%)*	*2 (1%)*	*<0.0001*		
Albumin, mg / dl. n (%)	*3.2 (2.9– 3.5)*	*2.91 (2.65– 3.13)*	*3.36 (3.06 – 3.64)*	*<0.0001*		
ALT> 40, U / L. n/N (%)	*59/189 (31%)*	*26 (48%)*	*33/135 (24%)*	*0.0015*	*2.87 (1.48 – 5.57) p=0·0018*	
LDH> 245, U / L. n/N (%)	*123/184 (67%)*	*53 (98%)*	*70/130 (54%)*	*<0.0001*	*45.43 (6.10 – 338.44) p=0·0002*	

Troponin I HS> 28, pg / ml. n/N (%)	*24/145 (17%)*	*23/50 (46%)*	*1/95 (1%)*	*<0.0001*	*80.07 (10.34 – 620.36) p=<0·0001*	
D-dimer>1, µg / mL. n/N (%)	*72/172 (42%)*	*44 (81%)*	*28/118 (24%)*	*<0·0001*	*20.04 (6.52 – 61.56) p=<0·0001*	*18.42 (2.64 – 128.55) p=0.0033*
Prothrombin time, ≥16. n/N (%)	*11/182 (6%)*	*7 (13%)*	*4/128 (3%)*	*0·0004*	*4.62 (1·29 – 16.50) p=0.019*	
Ferritin, ug / L (> 300). n/N (%)	*102/128 (80%)*	*44/46 (96%)*	*58/82 (71%)*	*0·0008*	*9.10 (2.04 – 40.58) p=0.0038*	
Interventions						
Steroid use. n (%)	*57 (30%)*	*26 (48%)*	*31 (23%)*	*0.0005*		
Immunoglobulin IV. n (%)	*46 (24%)*	*36 (67%)*	*10 (7%)*	*<0.0001*		
Oxygen by high flow nasal cannula. n (%)	*41 (21%)*	*33 (61%)*	*8 (6%)*	*<0.0001*		
Non-invasive MV. n (%)	*26 (14%)*	*24 (44%)*	*2 (1%)*	*<0.0001*		

Invasive VM. n (%)	*31 (17%)*	*31 (57%)*	*1 (1%)*	*<0.0001*		
ECMO. n (%)	*3 (2%)*	*3 (6%)*	*0*	*0.0054*		
Renal replacement therapy. n (%)	*10 (5%)*	*10 (19%)*	*0*	*<0.0001*		

IV: Intravenous; MV: mechanical ventilation; ECMO: Extracorporeal Membrane Oxygenation system; SOFA: Sequential Organ Failure Assessment

Table # 3. Poor prognosis indicators

PARAMETER	**VALUE**
Age	52 years (alive) vs 69 years (dead)
SOFA score	> 2.0
D-dimer	> 0.5 mg / L
Thrombocytopenia	<100,000
Prothrombin time	Increase> 3 seconds
Activated partial thromboplastin time	Increase> 5 seconds
Fibrinogen	<1.5 gm / l
Sepsis-Induced Coagulopathy (SIC) score	≥ 4
Respiratory frequency	> 24 bpm
Heart rate	> 125 bpm

Table # 4. ISTH score - Sepsis Induced Coagulopathy (*SIC*)

ITEM	SCORE	VALUE
Platelet count (X mm^3)	1	100.000 – 150.000
	2	< 100.000
PT - INR	1	1.2 – 1.4
	2	> 1.4
SOFA score	1	1
	2	≥ 2
	≥ 4	

Table # 5. Venous thromboembolism incidence studies for COVID-19 patients

Author, year	**n**	**Outcome**	**Tests**	**Treatment**	**Findings**
Cui S et al., 2020[23]	*81*	*Incidence of VTE in ICU*	*-rTR-PCR for SARS-COV-2* *-CT* *-LL venous Doppler ultrasound* *-Clinical examination* *-Laboratory tests*	*-Antiviral* *-Supportive* *-None* *-Thromboprophylaxis*	*-20/81 (25%) VTE* *-8/81 (10%) died* *-D-dimer cut-off point of 1.5ug/L for VTE with a S: 85%, E:88.6%, PPV: 70.8% and NPV: 94.7%*
Zhang L et al., 2020[24]	*143*	*Incidence of DVT in hospitalized*	*-LL venous Doppler ultrasound* *-Ecocardiography*	*-Antiviral* *-Antibiotic* *-Glucocorticoid*	*-66/143 (46%) DVT.* *-23/66 (34.8%)proximal DVT*

			-Laboratory test *-CT* *-Prediction scores for risk of VTE*	*-Antihypertensive* *-Immunoglobulin* *-Thromboprophylaxis*	*-43/66 (65.2%) distal DVT* *-CURB-65 score 3 to 5, Padua score ≥4 and D-dimer >1.o ug/mL for DVT screening with S: 88.52% and E: 61.43%.*
Middeldrop S et al., 2020[25]	*198*	*Incidence of VTE in hospitalized patients*	*-rTR-PCR for SARS-COV-2* *-CT* *-LL venous Doppler ultrasound* *-Laboratory test*	*-Thromboprophylaxis* *-Anticoagulation*	*-39/198 (20%) VTE* *-14/198 (7.1%) proximal DVT* *-11/198 (5.6%) distal DVT* *-13/198 (6.6%) PTE with/without DVT*
Klok FA et al., 2020[21]	*184*	*Incidence of the composite outcome of symptomatic acute PTE, DVT, ischemic stroke, myocardial infarction or systemic arterial embolism in ICU*	*-Laboratory test* *-LL venous Doppler ultrasound* *-CT angiogram*	*Thromboprophylaxis (nadroparin)*	*-31% cumulative incidence of composite outcome* *-27% cumulative incidence for VTE* *-3.7% cumulative incidence for arterial thrombotic events*
Lodigiani	*388*	*Rate of venous*	*-Laboratory test*	*Thromboprophylaxis*	*-28/362 (7.7%) at least*

C et al., 2020[13]		*and arterial thrombo embolic complication in hospitalized patients*	*-LL venous Doppler ultrasound* *-CT angiogram* *-ISTH score*		*one thromboembolic complication* *-16/362 (4.4%) VTE* *-9/362 (2.5%) ischemic stroke* *-4/362 (1.1%) acute coronary syndrome*

Table # 6. Cumulative incidence of VTE (24)

	Total VTE		**VTE in ICU**		**VTE in general ward**
	Asymptomatic	**Symptomatic**	**Asymptomatic**	**Symptomatic**	**Asymptomatic and symptomatic**
7 days	*16% (95% CI, 10-22)*	*10% (95% CI, 5.8-16)*	*26% (95% CI, 17-37)*	*15% (95% CI, 8.0-24)*	*(95% CI, 1.4-15)*
14 days	*33% (95% CI, 23-43)*	*21% (95% CI, 14-30)*	*47% (95% CI, 34-58)*	*28% (95% CI, 18-39)*	*9.2% (95% CI, 2.6-21)*
21 days	*42% (95% CI, 30-54)*	*25% (95% CI, 16-36)*	*59% (95% CI, 42-72)*	*34% (95% CI, 21-46)*	*9.2% (2.6-21)*

(Table # 7). Recommendations for thromboprophylaxis and / or anticoagulation

COVID-19 positive	Coagulation tests	Conventional thromboprophylaxis	Thromboprophylaxis in scalating doses	Anticoagulation
Ambulatory		Consider		
Hospitalized	X			
General ward	X	X		
ICU	X		X	
VTE confirmed	X			X
Confirmed PE	X			X
ARDS	X		X	

Table #8: Drug interactions (5, 7)



Graph # 1: Daily cases until September/2020. Comparison by regions



Image adapted from: https://covid19.who.int/

Graph # 2: Cumulative cases until September/2020. Comparison by regions



Image adapted from: https://covid19.who.int/

Graph # 3: Worldwide change of the Epicenter of the pandemic: Starting in Asia, then Europe and, currently, America (*North America and Latin America*)



Image adapted from: https://vac-lshtm.shinyapps.io/ncov_tracker/